Dzhndoian Z T
Ter Arkh. 2012;84(6):45-8.
The determination of serum myeloid-related protein MRP 8/14 (calprotectin) in Armenian patients with FMF before and after treatment with colchicine (including colchicine-resistant patients who don't respond to 2 mg of colchicine; t patients who don't respond to 1,5 mg of colchicine, and also responders to different dose of colchicine) and estimation of the response to antiinflammatory therapy.
MRP 8/14 serum levels were measured in 80 FMF patients before and after treatment with colchicine and in healthy individuals (n = 11) and patients with rheumatoid arthritis RA (n=11) as a control group. Serum MRP 8/14 concentration was measured by ELISA (Enzyme Linked-Immuno-Sorbent-Assay) method using "Buhlmann" kit (Switzerland) in the laboratory with modern equipment.
Serum MRP 8/14 concentrations were within a normal ranges in healthy individuals and elevated in patients with FMF and RA. MRP 8/14 serum levels in FMF patients were higher than in RA patients. Serum MRP 8/14 concentrations in FMF patients before colchicines therapy were higher than after treatment.
The findings of our study indicate that myeloid-related protein MRP 8/14 is a very sensitive marker of the disease activity and response to antiinflammatory therapy in FMF.
测定亚美尼亚家族性地中海热（FMF）患者在秋水仙碱治疗前后血清髓系相关蛋白MRP 8/14（钙卫蛋白）水平（包括对2毫克秋水仙碱无反应的秋水仙碱耐药患者、对1.5毫克秋水仙碱无反应的患者以及对不同剂量秋水仙碱有反应的患者），并评估抗炎治疗反应。
在80例FMF患者秋水仙碱治疗前后测定血清MRP 8/14水平，并测定11名健康个体及11名类风湿关节炎（RA）患者作为对照组。在配备现代设备的实验室中，使用瑞士“Buhlmann”试剂盒，通过酶联免疫吸附测定（ELISA）法测定血清MRP 8/14浓度。
健康个体血清MRP 8/14浓度在正常范围内，FMF患者和RA患者血清MRP 8/14浓度升高。FMF患者血清MRP 8/14水平高于RA患者。FMF患者秋水仙碱治疗前血清MRP 8/14浓度高于治疗后。
我们的研究结果表明，髓系相关蛋白MRP 8/14是FMF疾病活动和抗炎治疗反应的非常敏感的标志物。
